The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Germline genetic correlates in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) plus non-steroidal anti-androgen (NSAA) or enzalutamide (ENZA): Correlative study of ENZAMET (ANZUP 1304).
 
Anis Hamid
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer
Research Funding - Amgen; Convergent Therapeutics (Inst)
Travel, Accommodations, Expenses - Astellas Pharma
 
Monica Guilhaus
No Relationships to Disclose
 
Arun Azad
Honoraria - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hinova Pharmaceuticals (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Hinova Pharmaceuticals; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar
 
Jacqueline Rehn
No Relationships to Disclose
 
Emily Grist
No Relationships to Disclose
 
Edmond Kwan
Travel, Accommodations, Expenses - Astellas Pharma
 
Vinod Subhash
No Relationships to Disclose
 
Samantha Oakes
Patents, Royalties, Other Intellectual Property - Inventor on Australia Patent 'Methods for reducing or shutting down lactation in non human mammals and reagents therefore'; Inventor on US Patent 'methods for reducing or shutting down lactation in non human mammals and reagents therefore'; Royalty due to authorship contribution from Walter and Eliza Hall Institute for the partial sale of rights to licence Venetoclax (ABT-199)
 
James Kench
No Relationships to Disclose
 
Saud Aldubayan
No Relationships to Disclose
 
Eliezer Van Allen
Stock and Other Ownership Interests - ervaxx; Genome Medical; Genomic Life; Manifold Bio; Microsoft; Monte Rosa Therapeutics; Riva Therapeutics; Serinus Bio; Syapse; Tango Therapeutics
Consulting or Advisory Role - ervaxx; Genome Medical; Genomic Life; Illumina; Janssen; Manifold Bio; Monte Rosa Therapeutics; Novartis; Riva Therapeutics; Serinus Bio; Syapse; Tango Therapeutics; Tracer Bio
Speakers' Bureau - Illumina; TD Cowen
Research Funding - Bristol-Myers Squibb; Nextpoint (Inst); Novartis; Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent on clinical interpretation algorithms using cancer molecular data (Inst); Patent on discovery of chromatin regulators as biomarkers of response to cancer immunotherapy (Inst); Patent on discovery of retained intron as source of cancer neoantigens (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Martin Stockler
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma
 
Alexander Wyatt
Honoraria - AstraZeneca; Bayer; Janssen; Merck; Pfizer
Research Funding - ESSA (Inst); Promontory Therapeutics (Inst); Tyra Biosciences (Inst)
 
Gerhardt Attard
Honoraria - Astellas Pharma; Janssen; Janssen (I)
Consulting or Advisory Role - Abbott Laboratories; Amgen; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Therapeutics; ESSA; Ferring; Janssen-Cilag; Medivation; Merck; Merck Serono; Millennium; Novartis; Novartis; Pfizer; Ventana Medical Systems; Veracyte; Veridex
Speakers' Bureau - Astellas Pharma; AstraZeneca; Ferring; Ipsen; Janssen; Sandoz; Sanofi; Takeda; Ventana Medical Systems
Research Funding - Astellas Pharma (Inst); Blue Earth Therapeutics; Janssen (Inst); Novartis; Veracyte
Patents, Royalties, Other Intellectual Property - I am on The ICR rewards to inventors list of abiraterone acetate.; listed as inventor on docetaxel predictive biomarker (Veracyte); listed as inventor on patent related to blood biomarkers (UCL, Cancer Research Horizons)
Travel, Accommodations, Expenses - Abbott Laboratories; Amgen; Arvinas; Astellas Pharma; Astellas Pharma (I); AstraZeneca; Bayer; Bristol Myers Squib (I); ESSA; Ferring; Janssen; Janssen (I); Medivation; Merck Serono; Novartis; Orion Clinical; Pfizer; Propella Therapeutics; Sanofi; Ventana Medical Systems
Other Relationship - Institute of Cancer Research
 
Lisa Horvath
Employment - Connected Medical Solutions (I)
Leadership - ANZUP
Stock and Other Ownership Interests - Connected Medical Solutions (I); Imagion Biosystems
Honoraria - Amgen; ANZUP; Astellas Pharma; Bayer (Inst); Janssen
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma; Bayer
Research Funding - Astellas Pharma; Bayer (Inst); RedHill Biopharma (Inst)
Patents, Royalties, Other Intellectual Property - Provisional patent Australian No. 2022902527 Prognostic Markers (plasma lipid prognostic signature in metastatic prostate cancer). Inventors: Horvath L, Meikle P, Scheinberg S, Lin HM, Sullivan D The patent is owned by the Chris O'Brien Lifehouse (my (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; AstraZeneca; Bayer; Bayer; Janssen-Cilag; MSD Oncology; Pfizer
 
Ian Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); ESSA (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Johnson & Johnson/Janssen (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
(OPTIONAL) Uncompensated Relationships - ANZUP Cancer Trials Group
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix; Parthera
Consulting or Advisory Role - Advancell; Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Lilly; Novartis; Pfizer
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination; Parthenolide analogues as radiation protectors for non-cancer indications (e.g medical countermeasures) patent owned by University of Adelaide (Inst)